Related Experiment Video
Updated: Sep 20, 2026

Transradial Access Chemoembolization for Hepatocellular Carcinoma Patients
Published on: September 20, 2020
Apheresis in the treatment of cholesterol embolic disease
Midori Hasegawa1, Satoshi Sugiyama
1Department of Nephrology, Fujita Health University School of Medicine, Toyake, Aichi, Japan. mhase@fujita-hu.ac.jp
Insights
Cholesterol embolic disease management is improving. A protocol targeting embolism, cardiac failure, and cachexia, alongside therapies like corticosteroids and apheresis, shows promise for better patient outcomes.
Area of Science:
- Cardiovascular Medicine
- Nephrology
- Rheumatology
Background:
- Cholesterol embolic disease is a severe complication of atherosclerosis with no universally recommended treatment.
- Atherosclerosis can lead to cholesterol emboli, causing widespread organ damage.
Purpose of the Study:
- To review recent data on therapeutic protocols for cholesterol embolic disease.
- To evaluate the efficacy of drug therapy and apheresis in managing this condition.
Main Methods:
- Review of recent clinical data and therapeutic strategies.
- Analysis of drug therapy, including corticosteroids.
- Assessment of apheresis techniques, such as plasma exchange and LDL apheresis.
Main Results:
- A protocol addressing embolism, cardiac failure, and cachexia demonstrated favorable outcomes.
- Corticosteroids were beneficial in reducing inflammation.
- Combined plasma exchange and corticosteroid therapy showed effectiveness in multivisceral cases.
- Low-density lipoprotein (LDL) apheresis aided in skin and brain cholesterol embolism-induced damage.
Conclusions:
- Targeted therapeutic protocols can improve clinical outcomes in cholesterol embolic disease.
- Corticosteroids and apheresis are valuable adjuncts in managing this complex condition.
- Further research into comprehensive treatment strategies is warranted.
Abstract:
Cholesterol embolic disease is a devastating complication of atherosclerosis. Universally recommended treatment is lacking thus far. Recent data suggest that a therapeutic protocol aimed at specifically combating three causes of mortality, recurrent bouts of cholesterol embolism, cardiac failure, and cahexia, were associated with a favorable clinical outcome. As for drug therapy, corticosteroid has been reported to be beneficial in reducing local and general inflammatory responses. Concerning apheresis, combined therapy consisting of plasma exchange and low to intermediate-dose corticosteroid therapy has been shown to be effective in multivisceral cholesterol embolism. Low density lipoprotein (LDL) apheresis has been reported to be beneficial for cholesterol embolism-induced damage to the skin and brain.
Related Concept Videos
Lipid-Lowering Drugs: Statins and Miscellaneous Agents
Anticoagulant Drugs: Low-Molecular-Weight Heparins
Peripheral Artery Disease III: Interprofessional Care
Pulmonary Embolism II: Diagnostic Studies and Interprofessional Care
Cholesterol: Significance and Regulation
Considering cholesterol and...